| Bioactivity | ABT-299 is a prodrug of a platelet-activating factor (PAF) antagonist that exhibits significant inhibitory activity on PAF-induced β-platelet globulin release in vitro after in vivo administration in humans, an effect that may be partially attributed to the pyridine-N-oxide metabolite. |
| CAS | 161395-35-3 |
| Formula | C32H28ClFN4O4S |
| Molar Mass | 619.11 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ex vivo inhibition of PAF-induced beta-thromboglobulin release in man by ABT-299, a potent PAF antagonist [2]. Ex vivo inhibition of beta-thromboglobulin release following administration to man of ABT-299, a novel prodrug of a potent platelet activating factor antagonist |
ABT-299
CAS: 161395-35-3 F: C32H28ClFN4O4S W: 619.11
ABT-299 is a prodrug of a platelet-activating factor (PAF) antagonist that exhibits significant inhibitory activity on P
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.